Transarterial chemoembolization plus lenvatinib with or without protein-1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombus

Table 2 Treatment-related adverse events, n (%)

Category	Adverse events	Any grade			3 grade
		TACE-L-P	TACE-L	P value	TACE-L-P	TACE-L	P value
Total	Overall	34 (81.0)	37 (88.1)	0.546	9 (21.4)	6 (14.3)	0.569
Related to transarterial chemoembolization	Inguinal hematoma	3 (7.1)	2 (4.8)	> 0.999	1 (2.4)	0	> 0.999
	Nausea and vomiting	1 (2.4)	3 (7.1)	0.616	0 (0)	0 (0)	-
	Fever	2 (4.8)	4 (9.5)	0.676	0 (0)	1 (2.4)	> 0.999
	Abdominal pain	9 (21.4)	8 (16.7)	0.782	4 (9.5)	2 (4.8)	0.735
	Biliary injury	0	1 (2.4)	> 0.999	0 (0)	0 (0)	-
	New ascites	1 (2.4)	0	> 0.999	0 (0)	0 (0)	-
Related to drug	Diarrhea	12 (28.6)	8 (19.0)	0.442	4 (9.5)	3 (7.1)	> 0.999
	Thrombocytopenia	8 (19.0)	10 (23.8)	0.790	2 (4.8)	4 (9.5)	0.676
	Leukopenia	7 (16.7)	10 (23.8)	0.587	2 (4.8)	3 (7.1)	> 0.999
	Proteinuria	2 (4.8)	1 (2.4)	> 0.999	1 (2.4)	0 (0)	> 0.999
	Fatigue	9 (21.4)	7 (16.7)	0.755	2 (4.8)	4 (9.5)	0.675
	Hyperbilirubinemia	5 (11.9)	2 (4.8)	0.433	1 (2.4)	0 (0)	> 0.999
	Hypoalbuminemia	6 (14.3)	8 (19.0)	0.770	2 (4.8)	3 (7.1)	> 0.999
	Elevated aspartate aminotransferase	3 (7.1)	4 (9.5)	> 0.999	1 (2.4)	1 (2.4)	-
	Elevated alanine aminotransferase	4 (9.5)	3 (7.1)	> 0.999	1 (2.4)	0 (0)	> 0.999
	Oral ulcer	2 (4.8)	1 (2.4)	> 0.999	0 (0)	0 (0)	-
	Pneumonia	1 (2.4)	0 (0)	> 0.999	0 (0)	0 (0)	--
	Decreased appetite	6 (14.3)	3 (7.1)	0.483	2 (4.8)	1 (2.4)	> 0.999
	Elevated uric acid	2 (4.8)	0 (0)	0.493	1 (2.4)	0	> 0.999
	Insomnia	3 (7.1)	3 (7.1)	1.000	0 (0)	0 (0)	-
	Hyperglycemia	0 (0)	1 (2.4)	> 0.999	0 (0)	0 (0)	-
	Dysphonia	1 (2.4)	0 (0)	> 0.999	0 (0)	0 (0)	-
	Arthralgia	1 (2.4)	0 (0)	> 0.999	0 (0)	0 (0)	-
	Ventosity	2 (4.8)	0 (0)	0.494	0 (0)	0 (0)	-
	Hypertension	3 (7.1)	1 (2.4)	0.616	0 (0)	0 (0)	-

TACE-L: Transarterial chemoembolization combined with lenvatinib; TACE-L-P: Transarterial arterial chemoembolization combined with lenvatinib plus death protein-1 inhibitors.